Cargando…
A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma()
INTRODUCTION: Three-weekly cisplatin dose is accepted for standard treatment for concurrent chemo-radiotherapy in nasopharyngeal carcinoma. However, different chemotherapy schedules are presented in the literature. OBJECTIVE: We intend to compare toxicity and outcomes of high dose 3-weekly cisplatin...
Autores principales: | Gundog, Mete, Basaran, Hatice, Bozkurt, Oktay, Eroglu, Celalettin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422570/ https://www.ncbi.nlm.nih.gov/pubmed/31164277 http://dx.doi.org/10.1016/j.bjorl.2019.04.008 |
Ejemplares similares
-
The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Peng, Hao, et al.
Publicado: (2016) -
The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2015) -
Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand
por: Ngamphaiboon, Nuttapong, et al.
Publicado: (2020) -
Treatment effects of cumulative cisplatin dose during radiotherapy following induction chemotherapy in nasopharyngeal carcinoma: propensity score analyses
por: Peng, Liang, et al.
Publicado: (2020) -
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
por: Lv, Jia‐Wei, et al.
Publicado: (2018)